Zentalis Pharmaceuticals, Inc. (ZNTL)
| Market Cap | 289.02M +218.8% |
| Revenue (ttm) | n/a |
| Net Income | -124.13M |
| EPS | -1.74 |
| Shares Out | 71.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,934 |
| Open | 4.120 |
| Previous Close | 4.140 |
| Day's Range | 4.000 - 4.330 |
| 52-Week Range | 1.130 - 6.950 |
| Beta | 2.00 |
| Analysts | Buy |
| Price Target | 6.50 (+60.1%) |
| Earnings Date | May 12, 2026 |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 60.10% from the latest price.
News
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibi...
Zentalis Pharmaceuticals Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Azenosertib is advancing in registration trials for platinum-resistant ovarian cancer, with a 400 mg dose showing improved efficacy and tolerability. Companion diagnostic validation and commercial launch preparations are progressing, while pipeline expansion explores broader indications and combinations.
Zentalis Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer, with strong efficacy and safety at the 400 mg dose. The program includes expansion into combination therapies and a companion diagnostic, aiming for both accelerated and full approvals, and is positioned as a differentiated, non-chemo oral option for biomarker-selected patients.
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibi...
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trials DENALI Phase 2 tri...
Zentalis Pharmaceuticals Quarterly report: Q1 2026
Zentalis Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Zentalis Pharmaceuticals Earnings release: Q1 2026
Zentalis Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Zentalis Pharmaceuticals Slides: Corporate presentation
Zentalis Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrolling ASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval...
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibi...
Zentalis Pharmaceuticals Proxy statement: Proxy filing
Zentalis Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Zentalis Pharmaceuticals Proxy statement: Proxy filing
Zentalis Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June
Zentalis to present azenosertib preclinical data in TNBC at AACR meeting
Zentalis (ZNTL) announced data from two posters being presented at the 2026 American Association for Cancer Research Annual Meeting, taking place April 17-22, 2026, in San Diego, CA. The data…
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis price target raised to $10 from $6 at Guggenheim
Guggenheim raised the firm’s price target on Zentalis (ZNTL) to $10 from $6 and keeps a Buy rating on the shares, citing increased probability of success assumptions in platinum-resistant ovarian…
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups Azenosertib ther...
Zentalis Pharmaceuticals Slides: Corporate presentation
Zentalis Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 9, 2026.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phas...
Zentalis Pharmaceuticals Annual report: Q4 2025
Zentalis Pharmaceuticals has published its Q4 2025 annual report on March 26, 2026.
Zentalis Pharmaceuticals Earnings release: Q4 2025
Zentalis Pharmaceuticals released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Azenosertib is advancing in platinum-resistant ovarian cancer with ongoing DENALI and ASPENOVA trials, targeting cyclin E1-positive patients and aiming for accelerated and full approval. The MIRROR study will explore earlier-line combinations, while regulatory and operational milestones are on track.
Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Azenosertib is advancing in late-stage trials for PROC patients with high Cyclin E1 expression, targeting a 21,500-patient market in the US, EU4, and UK. The DENALI and ASPENOVA trials are on track, with consistent efficacy, manageable safety, and regulatory alignment for accelerated approval.